Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Number of Flu Patients Plunges to 1/1,200th of Pre-COVID Levels: Survey
February 28, 2022
- Horizon Launches Japan PIII for Thyroid Eye Disease Drug
February 25, 2022
- Fuji Pharma In-Licenses Sixth Biosimilar from Alvotech
February 25, 2022
- Shionogi Files COVID-19 Pill in Japan, Seeks Conditional Approval
February 25, 2022
- Tokyo Court Rejects Chugai’s Claim over Edirol Substance Patent
February 25, 2022
- Medicago’s COVID-19 Vaccine Approved in Canada
February 25, 2022
- Enhertu Hits PFS, OS Goals in HER2 Low Breast Cancer
February 22, 2022
- BTK Inhibitor Velexbru Approved in Taiwan: Ono
February 22, 2022
- Novo Prepping for Listing of Ozempic 2 mg Version amid Supply Curbs
February 22, 2022
- Bayer Gets Eylea Biosame Approval in Japan as It Braces for Biosimilar Debuts
February 22, 2022
- UCB Japan Recalls Antiepileptic Med E Keppra IV
February 22, 2022
- Sleep Inducer Recalls by Fuji Yakuhin, Tatsumi Kagaku Tied to Tokyo Wholesaler’s Fake API Case
February 21, 2022
- BMS Japan to Kick Off Workplace Booster Program in March
February 18, 2022
- Parmodia-Deberza Combo Improves NASH in Mice: Kowa/Univ. of Tokyo
February 18, 2022
- AstraZeneca to Discontinue Bydureon, Zestril amid Weak Sales
February 18, 2022
- Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
- Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
- GSK Launches Benlysta Observational Study in SLE Patients with History of Lupus Nephritis
February 17, 2022
- Healios Plans Preapplication Consultation with PMDA on MultiStem as Early as March
February 17, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…